On August 8th, Jingsin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the current centralized procurement covers only generic drugs. The differences in sales of innovative drugs are related to diseases, indications and so on. As the company's first innovative drug, we have equipped the best resources for the sales of Jingnoning. At the beginning of the launch, we focused on hospitalization and academic promotion, hoping to lay a solid foundation for future sales growth.
京新药业(002020.SZ)：目前集采涵盖的都是仿制药
Zhejiang Jingxin Pharmaceutical(002020.SZ): Currently, the centralized procurement covers only generic drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.